

July 15, 2013

The Honorable Barbara Boxer  
Chairman, Committee on Environment  
and Public Works  
United States Senate  
Washington, DC 20510

Dear Madam Chairman:

The U.S. Nuclear Regulatory Commission (NRC) is issuing an interim enforcement policy in the *Federal Register* that allows the staff to exercise enforcement discretion for certain medical event reporting violations under NRC regulations governing the medical use of byproduct material. This interim policy only applies to events occurring under a licensee's permanent implant brachytherapy program. Brachytherapy is a cancer treatment in which small radioactive sources are implanted inside or next to the area requiring treatment. This interim enforcement policy was developed based on recommendations for NRC's Advisory Committee on the Medical Use of Isotopes and the NRC's Medical Radiation Safety Team. The interim enforcement policy will be effective upon publication in the *Federal Register*, expected shortly.

Sincerely,

/RA/

Rebecca L. Schmidt, Director  
Office of Congressional Affairs

Enclosure:  
*Federal Register* Notice

cc: Senator David Vitter

July 15, 2013

The Honorable Thomas R. Carper  
Chairman, Subcommittee on Clean Air  
and Nuclear Safety  
Committee on Environment and Public Works  
United States Senate  
Washington, DC 20510

Dear Mr. Chairman:

The U.S. Nuclear Regulatory Commission (NRC) is issuing an interim enforcement policy in the *Federal Register* that allows the staff to exercise enforcement discretion for certain medical event reporting violations under NRC regulations governing the medical use of byproduct material. This interim policy only applies to events occurring under a licensee's permanent implant brachytherapy program. Brachytherapy is a cancer treatment in which small radioactive sources are implanted inside or next to the area requiring treatment. This interim enforcement policy was developed based on recommendations for NRC's Advisory Committee on the Medical Use of Isotopes and the NRC's Medical Radiation Safety Team. The interim enforcement policy will be effective upon publication in the *Federal Register*, expected shortly.

Sincerely,

/RA/

Rebecca L. Schmidt, Director  
Office of Congressional Affairs

Enclosure:  
*Federal Register* Notice

cc: Senator Jeff Sessions

July 15, 2013

The Honorable Fred Upton  
Chairman, Committee on Energy  
and Commerce  
United States House of Representatives  
Washington, DC 20515

Dear Mr. Chairman:

The U.S. Nuclear Regulatory Commission (NRC) is issuing an interim enforcement policy in the *Federal Register* that allows the staff to exercise enforcement discretion for certain medical event reporting violations under NRC regulations governing the medical use of byproduct material. This interim policy only applies to events occurring under a licensee's permanent implant brachytherapy program. Brachytherapy is a cancer treatment in which small radioactive sources are implanted inside or next to the area requiring treatment. This interim enforcement policy was developed based on recommendations for NRC's Advisory Committee on the Medical Use of Isotopes and the NRC's Medical Radiation Safety Team. The interim enforcement policy will be effective upon publication in the *Federal Register*, expected shortly.

Sincerely,

/RA/

Rebecca L. Schmidt, Director  
Office of Congressional Affairs

Enclosure:  
*Federal Register* Notice

cc: Representative Henry A. Waxman

July 15, 2013

The Honorable Ed Whitfield  
Chairman, Subcommittee on Energy  
and Power  
Committee on Energy and Commerce  
United States House of Representatives  
Washington, DC 20515

Dear Mr. Chairman:

The U.S. Nuclear Regulatory Commission (NRC) is issuing an interim enforcement policy in the *Federal Register* that allows the staff to exercise enforcement discretion for certain medical event reporting violations under NRC regulations governing the medical use of byproduct material. This interim policy only applies to events occurring under a licensee's permanent implant brachytherapy program. Brachytherapy is a cancer treatment in which small radioactive sources are implanted inside or next to the area requiring treatment. This interim enforcement policy was developed based on recommendations for NRC's Advisory Committee on the Medical Use of Isotopes and the NRC's Medical Radiation Safety Team. The interim enforcement policy will be effective upon publication in the *Federal Register*, expected shortly.

Sincerely,

/RA/

Rebecca L. Schmidt, Director  
Office of Congressional Affairs

Enclosure:  
*Federal Register* Notice

cc: Representative Bobby L. Rush

July 15, 2013

The Honorable John Shimkus  
Chairman, Subcommittee on Environment  
and the Economy  
Committee on Energy and Commerce  
United States House of Representatives  
Washington, DC 20515

Dear Mr. Chairman:

The U.S. Nuclear Regulatory Commission (NRC) is issuing an interim enforcement policy in the *Federal Register* that allows the staff to exercise enforcement discretion for certain medical event reporting violations under NRC regulations governing the medical use of byproduct material. This interim policy only applies to events occurring under a licensee's permanent implant brachytherapy program. Brachytherapy is a cancer treatment in which small radioactive sources are implanted inside or next to the area requiring treatment. This interim enforcement policy was developed based on recommendations for NRC's Advisory Committee on the Medical Use of Isotopes and the NRC's Medical Radiation Safety Team. The interim enforcement policy will be effective upon publication in the *Federal Register*, expected shortly.

Sincerely,

/RA/

Rebecca L. Schmidt, Director  
Office of Congressional Affairs

Enclosure:  
*Federal Register* Notice

cc: Representative Paul Tonko

July 15, 2013

The Honorable Barbara Boxer  
Chairman, Committee on Environment  
and Public Works  
United States Senate  
Washington, DC 20510

Dear Madam Chairman:

The U.S. Nuclear Regulatory Commission (NRC) is issuing an interim enforcement policy in the *Federal Register* that allows the staff to exercise enforcement discretion for certain medical event reporting violations under NRC regulations governing the medical use of byproduct material. This interim policy only applies to events occurring under a licensee's permanent implant brachytherapy program. Brachytherapy is a cancer treatment in which small radioactive sources are implanted inside or next to the area requiring treatment. This interim enforcement policy was developed based on recommendations for NRC's Advisory Committee on the Medical Use of Isotopes and the NRC's Medical Radiation Safety Team. The interim enforcement policy will be effective upon publication in the *Federal Register*, expected shortly.

Sincerely,

/RA/

Rebecca L. Schmidt, Director  
Office of Congressional Affairs

Enclosure:  
*Federal Register* Notice

cc: Senator David Vitter

**IDENTICAL LETTERS SENT TO:**

The Honorable Thomas R. Carper with cc: to Senator Jeff Sessions  
The Honorable Fred Upton with cc: to Representative Henry A. Waxman  
The Honorable Ed Whitfield with cc: to Representative Bobby L. Rush  
The Honorable John Shimkus with cc: to Representative Paul Tonko

**ADAMS Accession No.: ML13170A273**

OFFICE	ADM/DAS/RADB	ADM/DAS/RADB	ADM/DAS/RADB	OCA
NAME	DForder	LTerry	CBladey	RSchmidt
DATE	6/21/13	6/25/13	6/25/13	6/ 16 /13

**OFFICIAL RECORD COPY**